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Summary
In mice, Lkb1 deletion and activation of KrasG12D results in lung tumors with a high penetrance of
lymph node and distant metastases. We analyzed these primary and metastatic de novo lung
cancers with integrated genomic and proteomic profiles and have identified gene and
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Significance
While large-scale genomic analyses of non-small cell lung cancers (NSCLC) have yielded a better understanding of lung cancer
genetic alterations, studies defining the pathways deregulated in tumor progression and metastases are limited. LKB1 inactivation is
found in up to 30% of human NSCLC and Lkb1 deficient lung tumors in mice have a high penetrance of lymph node and distant
metastases. Our analyses of primary and metastatic Lkb1-deficient mouse lung tumors have shown that progression to metastatic lung
cancer is associated with unique gene and phosphoprotein signatures. In this work, we employ these signatures to design an effective,
rational therapeutic strategy to treat Lkb1-deficient lung cancers.
Microarray Data
Microarray data have been deposited at GEO with the accession number GSE21581.
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phosphoprotein signatures associated with Lkb1 loss and progression to invasive and metastatic
lung tumors. These studies revealed that SRC is activated in Lkb1 deficient primary and metastatic
lung tumors and that the combined inhibition of SRC, PI3K and MEK1/2 resulted in synergistic
tumor regression. These studies demonstrate that integrated genomic and proteomic analyses can
be used to identify signaling pathways that may be targeted for treatment.
Introduction
Lung cancer is the leading cause of cancer mortality worldwide. Genetic analyses and gene
expression profiling of primary human lung tumors have identified several aberrant
signaling pathways involved in the initiation of non-small cell lung cancer (NSCLC) (Bild et
al., 2006). While many of these pathways are also likely to be involved in NSCLC
progression and metastases, it is clear that the metastatic phenotype requires additional
pathway perturbations that regulate cell motility, cell adhesion, the epithelial to
mesenchymal transition (EMT), and extracellular matrix remodeling (Nguyen and
Massague, 2007). As the development of metastases causes much of the morbidity and
incurability of epithelial cancers, there is an urgent need to elucidate the events underlying
this biological process.
The paucity of matched primary and metastatic human lung tumors has made it difficult to
examine the genetic changes involved in the progression and metastasis of NSCLC. Studies
using genetically engineered mice have demonstrated that the activation of certain
combinations of oncogenes is sufficient for lung tumor initiation (Engelman et al., 2008;
Jackson et al., 2001; Ji et al., 2006a; Ji et al., 2006b) and that additional genetic events are
required for tumor progression (Iwanaga et al., 2008; Jackson et al., 2005) or metastases (Ji
et al., 2007; Kim et al., 2009). We recently showed that the loss of the Lkb1 tumor
suppressor gene in Kras-driven lung tumors results in metastases to lymph node and distant
sites in mice (Ji et al., 2007). Moreover, we and others, have shown that LKB1 is inactivated
by point mutations or deletions in at least 15-35% of NSCLC and concurrent KRAS and
LKB1 mutation is observed in 4-10% of NSCLC (Carretero et al., 2004; Koivunen et al.,
2008; Ji et al., 2007; Matsumoto et al., 2007; Sanchez-Cespedes et al., 2002).
In humans, germline mutation of LKB1 results in the Peutz-Jeghers syndrome, a familial
cancer syndrome characterized by intestinal hamartomas and an increased risk for epithelial
cancers, including lung cancers (Hearle et al., 2006). The LKB1 gene encodes a serine/
threonine kinase that phosphorylates several substrates, many of which are also kinases
(Alessi et al., 2006). However, identification of the pathways responsible for the pro-
metastatic effects of Lkb1 loss has yet to be elucidated.
To identify altered signal transduction pathways involved in the progression and metastases
of Lkb1 deficient lung tumors, we have performed an unbiased, integrated analysis of
genomic and phosphoproteomic signatures of primary and metastatic mouse lung tumors.
Results
Lkb1 deficient metastatic lung tumors harbor unique gene expression changes
Lung specific activation of mutant KrasG12D results in bronchoalveolar hyperplasia and low
grade adenocarcinomas (Jackson et al., 2001). We recently observed that concomitant loss
of the Lkb1 tumor suppressor gene leads to a broadened histologic spectrum of lung tumors
that have a high propensity for local invasion and metastases (Ji et al., 2007). To identify the
gene expression changes associated with the invasive and metastatic progression of Lkb1-
deficient mouse lung tumors, we compared RNA expression profiles from 9 Kras and 9
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Kras/Lkb1 primary tumors as well as 16 Kras/Lkb1 metastases (lymph node and distant
sites). Unsupervised hierarchical clustering of the samples revealed three distinct clusters
corresponding to the following groups: 1) primary lung tumors with activated Kras G12D, 2)
primary lung tumors with activated Kras G12D and Lkb1 loss, and 3) metastases from lung
tumors with activated Kras G12D and Lkb1 loss (Figure S1A).
To better characterize the molecular alterations associated with Lkb1 loss and metastasis we
derived expression signatures from our mouse lung tumors that reflected the gene expression
changes induced by Lkb1 loss in primary tumors (Lkb1) by comparing primary Kras tumors
to primary Kras/Lkb1 tumors and metastases (Mets) by comparing Kras/Lkb1 primary
tumors to Kras/Lkb1 metastases. We used a two-class unpaired differential expression
analysis and a false discovery rate (FDR) of <0.01. The resulting ‘Lkb1’ and ‘Mets’ gene
signatures contain 727 and 757 differentially expressed genes respectively (Figure 1A). In
aggregate, these results indicate that Lkb1 loss induces significant transcriptional changes in
primary cancers and that there are further gene expression alterations that characterize the
progression to lymph node and distant metastasis.
A cross species comparison across mouse and human datasets validates an expression
signature of metastases as prognostic in human NSCLC
We next sought to determine whether this Mets signature predicted clinical outcome in
human lung cancer patients. Using the human orthologs of the murine genes in the Mets
signature, we interrogated two publicly available gene expression datasets of primary
NSCLCs, annotated for either overall survival and histologic grade (Director's Challenge
Consortium dataset, Shedden et al., 2008) or metastasis free recurrence (MSKCC dataset 2,
Nguyen et al., 2009). The gene expression profiles of these human NSCLCs were queried
for the presence or absence of our Mets expression signature as defined by coordinate
upregulation and downregulation of overexpressed or under-expressed genes from the Mets
signature.
Consistent with the notion that our Mets gene signature correlates with a proclivity towards
metastasis, patients with tumors expressing the Mets signature had a significantly worse
survival and increased occurrence of metastasis than did patients with tumors without Mets
signature expression in these two datasets (Figure 1B). In contrast, the Lkb1 signature,
generated by comparing Kras tumors to Kras/Lkb1 primary tumors, had no prognostic value
(data not shown). These data suggest that the same gene expression changes induced during
progression of Lkb1 deficient tumors to metastases in this murine model faithfully
recapitulate those associated with the development of advanced incurable disease in human
primary NSCLC and might be useful to prognosticate patients with early stage lung cancer.
The disparity in the ability of the Lkb1 signature and the Mets signature in predicting
survival suggest that either there is a subset of cells in the primary tumor that is destined for
metastases which can not be discerned from expression analyses of the whole tumor or that
additional expression changes developed at the site of metastases from cancer-stromal cell
interactions. Lastly, and as shown on Figure S1B, the repressed component of the Mets
signature showed a strong and significant correlation with the human samples that are
mutant for both KRAS and LKB1 in the University of North Carolina dataset (Ji et al., 2007).
Lkb1 deficient metastases have upregulation of EMT-associated gene signatures
Activation of oncogenic signaling pathways has been shown to induce broad gene
expression changes that can be used to generate gene expression or metagene signatures
(Nevins and Potti, 2007). In order to better understand the biological basis for tumor
metastasis in this model, we compared genes that were upregulated in the metastatic
progression of these mouse lung tumors to known lists of transcripts associated with specific
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alteration in known pathways. Using gene set enrichment analyses, we identified gene
signatures that were significantly enriched in our Kras/Lkb1 metastases relative to our
primary Kras and Kras/Lkb1 lung tumors (Segal et al., 2004). Specifically, a collection of
curated gene sets (Table S1) provided by the Molecular Signatures Database (MsigDB,
broad.mit.edu/gsea/msigdb) and those collected from the literature (Ben-Porath et al., 2008;
Bild et al., 2006; Cole et al., 2008; Onder et al., 2008) were used to interrogate our gene
expression dataset using the Genomica analysis tool (genomica.weizmann.ac.il).
Thirty-two of the 51 curated, cancer-related, gene sets appeared to be significantly enriched
and highly expressed (p<0.05, FDR <0.05) in our dataset of Kras/Lkb1 metastases relative to
Kras and Kras/Lkb1 primary lung tumors (Figure 1C). This included a number of gene
signatures implicated in the metastatic process such as focal adhesion alterations, EMT,
increased TGF-β and β-catenin signaling, as well as embryonic stem (ES) cell expression
signature and transcription factors implicated in ES cell phenotype such as TCF3 and OCT4
(Ben-Porath et al., 2008; Bild et al., 2006; Cole et al., 2008; Onder et al., 2008). A number
of these findings were validated . For example, the canonical EMT markers (Kalluri and
Weinberg, 2009), Vimentin, Snail, Twist1, N-cadherin, Acta2, and fibronectin seen in this
signature were validated by RT-PCR (Figure S1C). Multiplex bead assay confirmed the
elevated TGF-β levels in lysates from Kras/Lkb1 metastases (Figure S1D). Furthermore,
immunostaining demonstrated the presence of canonical EMT markers such as vimentin and
fibronectin in both Kras/Lkb1 primary and metastatic tumors. (Figure S1E). While
components of these oncogenic signatures were observed in Lkb1-deficient primary tumors,
their levels appeared to be higher in Lkb1-deficient metastases (Figure 1C, Figure S1C, S1D,
and S1E). These results suggest that additional molecular events cooperate with Lkb1 loss to
maximally activate these pathways during metastatic progression.
Phosphoscan of LKB1-deficient cells identifies activation of SRC family kinases
To complement our transcriptional analysis, we assessed how loss of Lkb1 impacted tyrosine
kinase signaling cascades. We hypothesized that if Lkb1 loss resulted in significant
activation of specific tyrosine kinases, we should detect increased phosphorylation of their
respective substrates. To complement the analysis of murine tumors, we generated paired
LKB1 and control knockdown cells in the BEAS-2B human bronchial epithelial cell line
(Reddel et al., 1988), which is immortalized with SV40 Large T antigen, (BEAS-2B-
LKB1D and BEAS-2B-NT respectively) and in the K-RAS mutant, LKB1 wild-type NSCLC
cell line H358 (H358-LKB1D and H358NT), which has been previously shown not to
express markers of EMT (Thomson et al., 2008) (Figure 2A). These paired human cell lines,
along with our mouse lung primary and metastatic tumors, were used to generate
phosphotyrosine signatures using previously described methods (Rikova et al., 2007).
Specifically, whole cell extracts from cell lines or pooled tissue lysates (two pools with three
tumor samples each from Kras, Kras/Lkb1 primary tumors, and Kras/Lkb1 metastases) were
immunoprecipitated with a phosphotyrosine specific antibody, the immunoprecipitates were
then subjected to MS analysis to identify and quantify phospho-peptides.
We identified 441, 259, and 363 phosphotyrosine sites in BEAS-2B, H358, and mouse lung
tumors, respectively, that were enriched in the absence of LKB1 (Figure 2A). Forty one of
these LKB1-affected tyrosine phosphorylated peptides were noted to overlap across all 3
datasets (Figure 2A, cluster A), while an additional 26 peptides and 10 peptides were noted
to overlap between the BEAS-2B / mouse tumor and H358 / mouse tumor datasets
respectively (Figure 2A, clusters B and C). An examination of the putative upstream kinases
known to phosphorylate these tyrosine residues suggested that a number of kinases were
activated in association with LKB1 deficiency. These analyses pointed to a particularly
central role for SRC activation which was not only highly phosphorylated, but is also
predicted to be an upstream kinase for 13 sites of 40 differentially phosphorylated proteins
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among our datasets (Figure 2B). Moreover, Kras/Lkb1 primary tumors and metastases
showed a significant hyperphosphorylation of a Src substrates signature, as assessed by
GSEA analysis (Figure S2A).
The non-receptor tyrosine kinases, SRC and focal adhesion kinase, are activated by LKB1
loss
We speculated that integration of the gene expression and phosphoproteomics data sets
would be a powerful approach to identify functionally significant molecular alterations in
Lkb1 deficient lung cancers. We noted that gene signatures of focal adhesion activation were
highly enriched in metastases from Kras/Lkb1 lung tumors (Figure 1C). Focal adhesions are
dynamic subcellular structures known to mediate cell attachment to the extracellular matrix
and are composed of over 50 proteins including focal adhesion kinase (FAK or PTK2),
Paxillin, and SRC (Burridge et al., 1997; Playford and Schaller, 2004; Yeatman, 2004). As
noted above, SRC activation was the most prominent signature emerging from our
phosphoproteomic analysis and there was also strong evidence for FAK activation. To better
integrate our data examining the impact of LKB1 loss on the focal adhesion pathway,
components of the pathway upregulated at the gene expression or tyrosine phosphorylation
level were colored yellow and red respectively and visualized on a KEGG pathway map
(Figure 3). The results appear to show convergence on the activation of SRC, FAK, and
their downstream pathways by Lkb1 loss and implicate alterations in the expression and
activity of focal adhesion regulators in the pathogenesis of Lkb1 deficient lung cancers.
SRC and FAK activation results in focal adhesion disassembly and turnover, through
downregulation of RhoA, resulting in increased cellular motility (Arthur et al., 2000;
Yeatman, 2004). Given the key role of cellular motility and migration in the process of
metastasis, we next determined whether LKB1 regulates these key components of focal
adhesion dynamics. To this end, whole cell extracts of the H358 cells expressing control
shRNA (NT) or four different shRNA sequences targeting LKB1 (A, B, C and D) were
immunoblotted using antibodies against the activating tyrosine phosphorylation sites in
SRC, and FAK (Y416, and Y576/577 respectively). As shown in Figure 4A, LKB1
knockdown led to activation of the focal adhesion complex, specifically SRC and FAK.
Moreover, consistent with LKB1's established role as a regulator of the AMPK/TSC/
mTORC1 axis (Carretero et al., 2007; Shaw et al., 2004), H358 LKB1-deficient cells showed
an increase of AMPK (T172) and decrease of ACC (S79) phosphorylation, as well as an
increase of S6 (S240/S244) phosphorylation (Figure S3A).
Since Phosphoscan and Western blot analyses detect a phosphorylation site (Y416) that is
common to all SRC family kinases (SFKs) including SRC, FYN, LYN, LCK, HCK FGR
and YES, we interrogated the phosphorylation status of SFKs affected by LKB1 loss in
NCI-H358 and A549 cell lines using a Luminex bead assay. As shown in Figure S3B and
S3C, H358 cells preferentially activate SRC and LYN, whereas A549 activates only SRC. In
both cases, LKB1 loss promoted activation of SFKs. In addition, analyses of the protein
lysates from H358-LKB1D and H358-NT cells with a protein array with site specific
phospho-antibodies further validated SRC, FAK and other targets obtained by MS analyses
of Kras/Lkb1 murine model (Figure S3D).
These changes in SRC and FAK suggest impaired adhesion and increased cellular motility
(Yeatman, 2004). To assess whether loss of LKB1 affects the motility of these NSCLC cells,
we performed a scratch assay. H358 cells with LKB1 knockdown (LKB1D) migrated more
rapidly into the scratched space than the control cells (NT) while proliferation and viability
of the two cells lines were identical in vitro (Figure 4B, Figure S3E). LKB1 loss also
increased in vitro invasion of H358 cells, as assessed by Boyden chamber assay (Figure 4C).
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Therefore, loss of LKB1 appears to increase the kinase activity of several key proteins
involved in focal adhesion dynamics and promote cell motility and invasion.
We also determined the consequences of LKB1 loss in NSCLC cells in vivo. To this end,
H358-LKB1D and H358-NT cells were grown as subcutaneous xenograft tumors in nude
mice, and mean tumor volume was measured two weeks after implantation. Tumors derived
from H358 LKB1 deficient cells were significantly larger than those expressing a non-
specific shRNA, suggesting that loss of LKB1 promotes primary tumor growth in addition to
metastasis (Figure 4D). Immunohistochemical (IHC) staining with antibodies that
specifically recognize human (but not mouse) antigens showed increased levels of vimentin
in the H358-LKB1D xenografts than in the H358-NT tumors (Figure 4E), in agreement with
the previous results suggesting that loss of LKB1 promotes EMT (Figure 3A). Elevated
vimentin staining was particularly prominent at the edge of tumors suggesting that the EMT
in the LKB1 deficient tumor cells may have also involved signals from the adjacent stromal
cells (Figure 4E). In agreement to these observations, H358 cells without LKB1 (LKB1D)
released significantly more TGF-β1/2 than H358 control (NT) cells and nuclear β-catenin
accumulation was more prevalent in LKB1D than in NT cells (Figures S3F and S3G). These
observations support the notion that LKB1 loss plays an important role in EMT.
LKB1 loss heightens dependence on SRC and FAK signaling for cell adhesion and
migration
Our integrated gene expression and Phosphoscan results suggest that LKB1 loss might
promote metastasis through activation of SRC and FAK signaling. Metastasis is a multi-step
process involving cell interactions with extracellular matrix (ECM) components, increased
cell migration and tumor invasion (Mitra and Schlaepfer, 2006). These individual processes
can both modulate and be modulated by SRC and FAK activity (Huveneers and Danen,
2009; Shibue and Weinberg, 2009). We hypothesized that SRC/FAK activation induced by
LKB1 loss resulted in an increased dependence upon these signaling pathways for cell
adhesion to ECM. To test this hypothesis, 5×105 cells with or without LKB1 knockdown
were plated on tissue culture wells coated with either collagen I, collagen IV, fibronectin,
laminin I, fibrinogen or BSA in the presence of the SRC-family kinase inhibitor, Dasatinib,
or the FAK inhibitor, PF573228 (Johnson et al., 2005; Slack-Davis et al., 2007). among the
ECM components tested, only collagen I or IV were able to promote the adherence of H358
cells (Figure 5A and data not shown). Knockdown of LKB1 in H358 cells did not have an
appreciable effect on the baseline adhesion of H358 cells to either collagen I or IV.
However, treatment of H358 cells with Dasatinib or PF573228 resulted in a dose-dependent
decrease in cell adhesion that was more prominent in H358 cells with LKB1 knockdown
(Figure 5B). Similar results were obtained when H358 cells with or without LKB1
expression were examined for the effects of Dasatinib and PF573228 on cell migration
(Figure 5C). These observations support the notion that the activation of SRC and FAK due
to LKB1 loss promotes dependence upon these signaling pathways for cell migration and
adhesion to extracellular matrix components as well as migration.
Combined inhibition of PI3K-mTOR, MEK, and SRC family kinases results in synergistic in
vivo tumor response in LKB1 defective lung tumors
We had previously observed that dual inhibition of PI3K-mTOR and MEK using BEZ235 (a
PI3K-mTOR inhibitor) and AZD2644 (a MEK1/2 inhibitor) resulted in an 80% reduction of
tumor volume of Kras dependent murine lung tumor model (Engelman et al., 2008).
Surprisingly, treatment of Kras/Lkb1 mice with the same combination showed that these
lung tumors were largely unresponsive (Figure 6A). Since our integrated gene expression
and phosphotyrosine profiling as well as in vitro cell culture studies demonstrated that SRC
is activated by LKB1 loss (Figure 1C, Figure 2B, Figures S2 S3A, S3B and S3C), we
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hypothesized that inhibition of SRC by Dasatinib might restore sensitivity of Kras/Lkb1
lung tumors to PI3K and MEK inhibition. To examine the therapeutic impact of SRC
inhibition in Kras/Lkb1 lung cancers, we treated established Kras/Lkb1 lung cancers with
Dasatinib alone, the combination of BEZ235 and AZD2644 (AZD/BEZ), or the combination
of all three agents (Dasatinib/AZD/BEZ). While Kras/Lkb1 lung tumors did not respond to
Dasatinib or BEZ/AZD, the triple combination Dasatinib/BEZ/AZD resulted in significant
tumor regression as detected by serial MRI imaging (Figure 6A) and histology (Figure 6B).
This in vivo data suggests that Lkb1 loss results in reduced sensitivity to the combined
inhibition of PI3K and MEK, at least in part, through activation of SRC. Moreover, although
Dasatinib alone in Kras/Lkb1 lung cancer model did not provide overall survival benefit
over vehicle in this Kras/Lkb1 lung cancer model, it blocked metastasis (Table S2).
Gene expression profiling of short term treated tumors showed that all treatments were able
to revert Lkb1 and Mets signatures (Table S2). Interestingly, Dasatinib alone induced
downregulation of SRC, TGF-β and MEK signatures, but not AKT, EMT and ES signatures.
Triple combination downregulated SRC, TGF-β, MEK as well as AKT, EMT and ES
signatures. This analysis supports the observation that Dasatinib synergizes with BEZ/AZD
in inhibiting signal transduction pathways that are important in the proliferation and survival
of Kras/Lkb1 driven cancer cells.
Discussion
Cancer genomic studies have established a number of oncogene and tumor suppressor
pathways as important for the initiation and maintenance of neoplastic lesions in NSCLC.
However, the molecular alterations necessary for invasion and metastasis of NSCLC are less
well-defined. We have previously reported that deletion of the Lkb1 tumor suppressor gene
in the context of Kras-driven murine lung tumors promotes invasion and metastasis (Ji et al,
2007). Here we extend these findings to show that Kras/Lkb1 primary and metastatic tumors
have upregulated expression of markers and inducers of EMT. Furthermore, through an
integrated genomic and phosphoproteomic analysis of mouse lung primary and metastatic
tumors, we have determined that two key modulators of focal adhesion dynamics, SRC and
FAK, are upregulated by Lkb1 loss during NSCLC progression. Similarly, LKB1 loss in
vitro also resulted in SRC activation, increased motility and SRC-dependent adhesion. In
fact, migration was selectively abrogated by SRC and FAK inhibition in LKB1 deficient
cells. Finally, while Kras mutant lung tumors are sensitive to the combined inhibition of the
PI3K and MEK pathways, we have found that Kras/Lkb1 tumors are resistant to these
inhibitors, and that sensitivity can be restored by additional targeting of SRC. It also
important to note that addition of Dasatinib to combined PI3K/MEK inhibition induced
tumor shrinkage in the Lkb1 deficient tumors. This reveals an important role for SFKs in
tumor growth and promoting resistance to combined PI3K/MEK inhibition. Indeed, in
addition to their prominent roles in tumor migration and adhesion, SFKs are also essential
for transducing signals from RTKs and integrins to promote cell survival and proliferation
(Yeatman, 2004). It was somewhat surprising that single-agent Dasatinib led to increased
volume of Kras/Lkb1 tumors (Figure 6) and persisting Akt and EMT signatures (Table S3).
Although we cannot fully explain this observation, it is tempting to speculate that SRC
inhibition led to loss of a feedback mechanism resulting in increased tumor growth or to a
change in the interactions between tumor cells and stroma or immune cells resulting in
tumor growth. Collectively, these results point towards a mechanism underlying the
increased propensity for metastases seen in Lkb1 deficient lung tumors and identify SRC as
a molecularly targetable pathway for the treatment of LKB1-deficient NSCLC in humans.
Tumor metastasis is a complex, multistage process that involves both initiating functions,
such as invasion and angiogenesis, as well as metastasis progression functions such as
Carretero et al. Page 7
Cancer Cell. Author manuscript; available in PMC 2011 June 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
extravasation and survival (Nguyen and Massague, 2007). EMT has been implicated in
metastasis initiation and involves loss of cell-cell junction proteins as well as a conversion
of stationary cells to motile cells capable of invading through the ECM (Yang and
Weinberg, 2008). Our gene expression analysis suggests that LKB1 loss results in the
aberrant expression of a number of oncogenic pathways and transcription factors known to
be inducers of EMT such as SNAI1, TWIST1, and the TGF-β and β-catenin pathways
(Kalluri and Weinberg, 2009; Nguyen and Massague, 2007; Yang and Weinberg, 2008).
While the mechanism by which LKB1 loss promotes EMT remains to be determined, we
observe that NSCLC cells lacking LKB1 exhibit higher nuclear localization of β-catenin and
increased release of TGF-β (Figures S3F and S3G) suggesting that LKB1 loss may have a
direct cell autonomous role in promoting the EMT program. The expression signatures
derived from Kras/Lkb1 metastasis enriched for EMT correlate with NSCLC patients with
metastatic potential and worsened survival (Figure 1B) while expression signatures derived
from Kras primary tumors or Kras/Lkb1 tumors did not correlate with survival thus have no
prognostic values. Importantly, the presence of Mets signature in primary tumor samples,
including a subset of double KRAS and LKB1 mutants, suggests that a subset of primary
tumors harbor cells destined for metastasis.
Part of the roadblock in defining the pathways involved in invasion and metastases in human
NSCLC has been the difficulty in obtaining tissue from metastatic sites. Through the use of
a Kras-driven, Lkb1-deficient genetically engineered mouse model of lung cancer, we have
been able to collect matched primary and metastatic tumors and apply integrated gene
expression and phosphoproteomic analysis to define altered signal transduction pathways.
The utilization of complex murine cancer models to identify signal transduction pathways
altered in cancer progression and metastases might serve as a paradigm for other solid
tumors that suffer from similar barriers to tissue acquisition.
Previous work from our lab has shown that dual inhibition of the PI3K and MEK pathways
in Kras driven murine NSCLC results in synergistic tumor responses (Engelman et al.,
2008). Strikingly, Lkb1 loss renders these tumors substantially more resistant to this
therapeutic regimen; therefore Lkb1 loss could serve as a negative predictor of the responses
to the therapy. Despite the broad gene expression changes seen in the setting of Lkb1 loss
and progression to metastases, it is notable that we were able to define a candidate mediator
of Lkb1-deficient tumor growth, SRC, in which additional inhibition — with Dasatinib—
was able to restore sensitivity to inhibition of PI3K and MEK in vivo. A limitation of this
analysis is that Dasatinib is a potent inhibitor of other kinases, e.g. ABL, which was also
activated to a lesser degree in Lkb1-deficient tumors. Future studies will determine the
relative importance of SFKs vs. other Dasatinib targets in mediating the response to this
agent. Lastly, Kras/Lkb1 mice treated with Dasatinib alone did not show any evidence of
metastasis (Table S2). This further reinforces our data that the Src family members are
important mediators of metastatic progression in Kras/Lkb1 driven lung cancer. In
conclusion, our results imply that despite the complex transcriptional and signaling changes
that occur in the setting of LKB1 loss and progression of NSCLC, these tumors may still be
addicted to isolated oncogenic events that can be successfully therapeutically targeted.
Experimental Procedures
Mouse colony and tumor collection
All mice were housed and treated in accordance with protocols approved by the institutional
care and use committees for animal research at the Dana-Farber Cancer Institute. Kras and
Kras/Lkb1 mice were treated with 5×106 p.f.u. adeno-Cre (University of Iowa viral vector
core) intranasally as previously described (Ji et al., 2007). Primary lung adenocarcinomas
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and metastases were macrodissected and formalin fixed or frozen in liquid nitrogen and
stored at −80° until use.
Histology and Immunohistochemical analysis
Formalin fixed tissues were paraffin embedded, sectioned at 5 μm, and haematoxylin and
eosin stained (Department of Pathology in Brigham and Women's Hospital). Unstained
slides were deparaffinized in xylene and rehydrated sequentially in ethanol. Antigen
retrieval was performed by boiling slides in 10mM sodium citrate (pH 6.0) for 30 minutes.
Primary antibodies were diluted in TBST with 5% goat serum and incubated overnight at
4ºC (see Supplemental experimental procedures for detailed list of primary antibodies).
Detection was performed using the avidin-biotin horseradish peroxidase technique in which
3,3”-diaminobenzidine was the chromogenic substrate.
Analysis of microarray gene expression data
Gene expression profiling methods (Total RNA isolation and microarray processing) are
available in Supplemental Methods. Clustering and differential expression analyses were
performed using the Gepas Analysis suite (Tarraga et al., 2008) and GenePattern (Reich et
al., 2006) with procedures described in Supplemental methods. Genomica software
(http://genomica.weizmann.ac.il/) was used to identify enrichment patterns of a custom
collection of experimental signatures associated with different phenotypes and cancer-
related events (Ben-Porath et al., 2008; Segal et al., 2004) (see Table S1 for detailed
description). Briefly, the data was log2 transformed and mean-centered. Genes whose
expression was 2 fold or greater than the mean expression level were scored. Enrichment of
overexpressed or underexpressed genes that belong to each tested gene signature was
calculated using a hypergeometric test and a false discovery rate (FDR) calculation to
account for multiple hypothesis testing. (P < 0.05, FDR<0.05). Finally, the fraction of
tumors showing significant enrichment for a particular gene signature in each class (Kras
tumors, Kras/Lkb1 primary tumors and metastasis) was calculated and assigned a P value
according to the hypergeometric distribution (P < 0.01, FDR<0.05).
Gene Set Enrichment analysis of short term treated Kras/Lkb1 tumors was performed using
GSEA (broad.mit.edu/gsea) across the complete list of genes ranked by signal-to-noise ratio.
UNC human lung cancer microarrays (Agilent custom 44,000 probe) annotated with KRAS
and LKB1 genetic status were mapped to mouse genes using NCBI Homologene, retaining
only one-to-one orthologs. Microarray data were sample and gene standardized, and Lkb1
and Mets signature scores were calculated as the median of the genes across the gene set.
Statistical significance was calculated using the Wilcoxon rank sum test.
Survival analysis
The Director's Challenge Consortium human primary lung adenocarcinoma dataset was
downloaded from caarraydb.nci.nih.gov (experiment ID 1015945236141280:1) (Shedden et
al., 2008). MSKK dataset 2 was downloaded from cbio.mskcc.org/Public/lung_array_data
(Nguyen el al., 2009). Datasets were first log2 transformed, mean-centered dataset and
loaded into Genomica software. Enrichment of genes that belong to our murine derived
Mets signature was calculated as described above and each patient was assigned an
enrichment score. Positive and negative enrichment scores for each individual were matched
with survival data (time to last contact or death) or recurrence of metastasis (metastasis free
survival). Kaplan-Meier plots were created with Graphpad software. Statistical significance
was calculated using the log rank test.
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Phosphopeptide immunoprecipitation, LC-MS/MS and phosphopeptide analysis
We performed phosphotyrosine peptide identification and quantification as described
previously (Rikova et al., 2007). See Supplemental Methods for sample preparation and
handling. For differential phosphorylation analysis, duplicated intensities were averaged,
and fold-changes between different experimental conditions were calculated. For KEGG
classification of the phosphoproteins, we used FatiGO software (www.babelomics.org) (Al-
Shahrour et al., 2004). A modification of the Gene Set Enrichment Analysis (GSEA)
(Subramanian et al., 2005) using phosphoprotein sets instead gene sets (Figure S2A) was
used to interrogate the PhosphoPoint database of tyrosine kinase substrates
(kinase.bioinformatics.tw) (Yang et al., 2008).
Quantitative RT-PCR
50 ng RNA of total RNA was reverse-transcribed with the Superscript cDNA Synthesis Kit
(Invitrogen). Real time PCR reactions were prepared in triplicate for each sample using
primers and TaqMan probes purchased from Applied Biosystems (see also Supplemental
Experimental Procedures). Reactions were run on an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems). GAPDH was used as a reference for all reactions.
Relative levels of a gene was determined by ΔΔCt method.
Multiplex bead analysis
Quantification of TGF-β isoforms and Src family kinase activities were assayed using
Human TGF-β 1,2,3 Assay and SRC Family Kinase 8-Plex (Millipore), respectively. Assays
were performed according to the manufacturer's specifications and analyzed with a Luminex
100 platform. Fluorescence intensity from duplicate samples was averaged and transformed
into protein concentration using a calibration curve obtained with TGFβ1, 2 and 3 standards.
For Src assay, activity was expressed in mean fluorescence intensity (MFI) with background
correction from duplicate samples. Statistical significance was calculated using a two-sided
Student's exact t-test.
Western blot and kinase array analysis
Parameters for Western blot and antibodies are available in Supplemental Experimental
Procedures.. Human phospho-kinase arrays (R&D Systems) were performed according to
the manufacturer's instructions. The percent control activation/deactivation was determined
by densitometric analysis using ImageJ Software (NIH).
Short hairpin RNA constructs, lentiviral infection, and small interfering RNA infection
Short hairpin RNA (shRNA) constructs cloned in pLKO.1 puro vector were designed by the
RNAi consortium and distributed by Open Biosystems. shRNA sequences are provided with
supplemental experimental procedures. Stable polyclonal cell lines are established as
described previously (Shimamura et al., 2008).
Cell migration, invasion and adhesion assays
Cell migration in cultures was measured using a two-dimensional in vitro scratch motility
assay. 1mm wide scratch was made on confluent monolayer in tissue culture slides and
allowed to grow under standard conditions for 12 h. Repopulation of the cleared field was
recorded using a Nikon inverted TE2000 and migrated distance was quantified using Image
J software. Invasion and adhesion assays kits were obtained from Cell Biolabs and assays
were performed according to manufacturer's specifications. Details are available in
Supplemental Methods.
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Immunofluorescence analysis
Cells were fixed on four-well chamber glass slides in methanol/acetone (1:1) at –20°C for
10 min and air-dried. Primary block was done with 10% goat serum (Sigma) and 0.05%
Tween 20 in PBS buffer for 1 hour at room temperature. A mouse monoclonal antibody for
activated β-catenin (Millipore) was diluted 1:50 in blocking buffer and incubated overnight
at 4°C. Rabbit anti-mouse secondary antibody conjugated with Alexa488 dye (Invitrogen)
was diluted 1:100 in blocking buffer and incubated for 1 h at room temperature. Images
were acquired using a Nikon inverted TE2000 microscope equipped a Hamamatsu Orca ER
digital CCD camera.
In Vivo Xenograft Experiments
Five-to 6-week-old female nu/nu mice (Charles River) were maintained under pathogen-free
conditions. Tumors were generated by injecting s.c. 5×106 cells mixed with reconstituted
basement membrane Matrigel (BD Biosciences) with 1:1 ratio in PBS. Animals were
sacrificed 14 days after inoculation, and tumors were excised and fixed in formalin. Tumor
measurements were obtained using electronic calipers. Tumor volume was calculated using:
Tumor volume = (length × width2)/2. We compared tumor volumes of mice using a two-
sided Student's exact t-test.
Cancer therapy using inhibitors
Dual PI3K-mTOR inhibitor, NVP-BEZ235-AN (Novartis Institutes for Biomedical
Research) was reconstituted in one volume of N-methyl-2-pyrrolidone (69118, Fluka) and
nine volumes of PEG300 (81160, Fluka) and administered by oral gavage. MEK inhibitor
ARRY-142886 (AZD6244, Otava Chemicals) and Dasatinib (LC Labs) were reconstituted
in 0.5% methyl cellulose (Fluka) and 0.4% polysorbate (Tween 80; Fluka) and administered
by oral gavage. Dosages are indicated in the figure legends.
Magnetic resonance imaging and tumor volume measurement
We performed MRI measurements as described previously (Engelman et al., 2008). Brief
descriptions are available in supplemental methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A gene expression signature of metastasis derived from a Kras-driven, Lkb1-deficient
mouse lung cancer model predicts survival in human NSCLC
A. Generation of an expression signature of metastasis. Kras/Lkb1 primary tumors were
compared to Kras/Lkb1 metastases using two-class unpaired differential expression analysis
and a false discovery rate (FDR) of <0.01. A total of 757 unique transcripts were
significantly differentially deregulated and used to define a metastatic gene signature (Mets).
B. Kaplan-Meier analysis of the Director's Challenge Consortium dataset (N=180) and
Memorial Sloan Kettering Cancer Center dataset 2 (N=98) of human lung tumors comparing
the overall survival between tumors showing activation (red line) or inactivation (green line)
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of our mouse derived Mets signature. Red line = Mets signature activated. Green line = Mets
signature inactivated.
C. Heat map of relative enrichment scores derived by gene set enrichment analysis. Tumors
are represented in columns and genes signatures are represented in rows (red = significant
enrichment of overexpressed genes; green, significant enrichment of under-expressed genes;
black, not significant; p<0.05). The right panel shows the aggregate enrichment scores for
each of the three classes of tumors (Kras, Kras/Lkb1 primary tumors and Kras/Lkb1
metastases).
See also Table S1 and Figure S1.
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Figure 2. Phosphoprotein profiling of human cell lines and murine tumors
A. Venn diagram of phosphotyrosine sites identified in Kras/Lkb1 primary versus metastatic
murine tumors and isogenic paired cell lines (NCI-H358 and BEAS-2B) expressing shRNA
to LKB1 (LKB1D) or a non-targeting shRNA (NT). Western blots show the effectiveness of
LKB1 knockdown (LKB1D) in NCI-H358 and BEAS-2B cells. Red numbers in brackets
show differentially increased or decreased phosphotyrosine sites in each comparison.
B. Table of coordinately regulated, LKB1 dependent, phosphotyrosine sites. Details of the
LKB1 dependent phosphotyrosine sites found to be coordinately regulated across datasets
are listed and include the phosphorylated protein, the tyrosine site, heatmaps of log2 ratios of
indicated comparisons (red, positive log2 ratios; blue, negative log2 ratios), as well as the
Carretero et al. Page 17
Cancer Cell. Author manuscript; available in PMC 2011 June 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
putative upstream kinase. The GEP (gene expression profiling) data column indicates the
level of expression of the genes encoding these proteins between Kras/Lkb1 (primary or
mets) versus Kras murine tumors comparisons (red dots = significantly overexpressed, green
dots = significantly underexpressed, and orange dots = no significant change). 1 Upstream
kinases obtained from PhosphoELM, HPRD and Swissprot databases; 2 Upstream kinases
obtained from NetworKIN database. See also Figure S2.
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Figure 3. Focal adhesion is impaired in Kras/Lkb1 tumors and metastases
Most relevant findings from our genomic and proteomic analysis were depicted on the focal
adhesion KEGG pathway. Proteins labeled in red were hyperphosphorylated in the
Phosphoscan analysis comparing Kras/Lkb1 primary tumors and metastases within the
Phosphoscan analysis comparing Kras/Lkb1 primary tumors and metastases with Kras alone
tumors. (Figure 2B). Proteins labeled in marked orange were found overexpressed (or their
signatures were enriched) in the gene expression profiling comparing Kras/Lkb1 primary
tumors and metastases with Kras alone tumors (Figures 1A and 1C).
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Figure 4. LKB1 knockdown activates EMT markers, mediators of focal adhesion dynamics and
enhances cell motility
A. Western blot analysis of NCI-H358 cells (LKB1 wild-type, KRAS G12C mutant) infected
with lentiviruses encoding 4 different sequences of shRNAs (A-D) targeting LKB1 or non-
targeting shRNA (NT). Whole cell lysates were imunoblotted with antibodies specific to
LKB1 or tyrosine specific antibodies against SRC (Total and Y416), FAK (Total and Y576),
paxillin (Total and Y118), E-Cadherin, and vimentin. α/β-actin (Actin) serves as a loading
control.
B. Representative photographs of scratched areas of confluent monolayers of NCIH358 cells
expressing a shRNA to LKB1 (LKB1D) or a non-targeting shRNA (NT) 12 hours after
wounding with a pipet tip.
C. NCI-H358 cells expressing shRNA to LKB1 (LKB1D) or non-targeting shRNA (NT)
were subjected to invasion assay in Boyden chambers coated with matrigel for 48 hours
using 10% FBS as chemoattractant. Data is graphed as mean of 3 replicates ± SD.
D. Mean tumor volume measurements of NCI-H358 xenografts. The human lung cancer
cells, NCI-H358, expressing shRNA to LKB1 (LKB1D) or a non-targeting shRNA (NT)
were grown subcutaneously in athymic nude mice. After 14 days the tumors were measured
and the tumor volume calculated (error bars = 1 SD; n=5, p=0.043).
E. Immunohistochemical staining of human vimentin and human cytokeratins in NCIH358
NT and LKB1D xenografts. See also Figure S3.
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Figure 5. LKB1 knockdown cooperates with FAK and SRC inhibition to prevent adhesion to
Collagen and migration in NCI-H358 cells
A. Exponentially growing NCI-H358 cells expressing shRNA to LKB1 or a nonspecific
shRNA (NT) were seeded at 5×105 cells in wells coated with collagen I, collagen IV, or
BSA and allowed to adhere to the matrices in the presence of DMSO (control), 10nM
Dasatinib (SRC inhibitor) or 100nM PF 573228 (FAK inhibitor) . After 90 minutes, loose
cells were washed off and adherent cells were fixed and stained.
B. NCI-H358 cells expressing shRNA to LKB1 (LKB1D) or a non-specific shRNA (NT)
were seeded at 1×105 cells/well onto collagen I coated 96 well plates containing DMSO or
increasing concentrations of Dasatinib or PF573228, and incubated for 90 minutes. Data
points represent the average of normalized values expressed as % of adhesion compared to
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DMSO-treated cells, from two independent experiments performed in triplicate; error bars =
SD.
C. NCI-H358 cells expressing shRNA to LKB1 (LKB1D) or a non-specific shRNA (NT)
were seeded at 1×105 cells/well onto 24well and cells were allowed to grow until forming
confluent monolayers. The monolayer was scratched with a pipet tip to form a wound and
the cells were grown in media containing DMSO or increasing concentrations of Dasatinib
or PF573228. 12 hours after wounding of the confluent monolayers, the wound closure was
measured and expressed as % closure of the original wound. Data is graphed as mean of 3
replicates ± SD.
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Figure 6. Combination therapy with PI3K, MEK, and SRC inhibitors results in synergistic in
vivo response of Lkb1 deficient murine lung tumors
A. Representative MRI images before and after treatment for each group. Mice in each
group were MRI imaged then treated daily for two weeks with the following doses: 45 mg/
kg of BEZ235, 25mg/kg of AZD6244 and 15 mg/kg of Dasatinib and imaged again. Tumor
volumes were normalized to pretreatment tumor volumes. The average tumor volumes of
3-7 mice in each treatment group are shown. Error bars = 1 SD (p < 0.05 BEZ/AZD/
Dasatinib-treated versus pretreatment).
B. H&E staining. H&E sections of representative Kras/Lkb1 tumors from animals treated
with the indicated drugs. See also Tables S2 and S3.
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